Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237809 · ClinicalTrials.gov registry record · Phase 3
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
A Phase 3 study of Schizophrenia and Schizoaffective Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 2
- Study locations
NCT00237809 is a Phase 3 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Yale University. The registered enrollment target is 104 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00237809, a Phase 3 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG D-serine
- BEHAVIORAL Cognitive Retraining (CRT)
- BEHAVIORAL Cognitive Retraining Placebo
Study Locations (2)
Connecticut
- Connecticut Mental Health Center - New Haven
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2002-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237809
The ClinicalTrials.gov registry entry for NCT00237809 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00237809 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00237809 about?
NCT00237809 is a clinical study titled "D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia". This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained bene...
What is the current status of trial NCT00237809?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2002-09. Estimated completion is 2012-09.
What conditions does trial NCT00237809 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT00237809?
The interventions under investigation include: Placebo (DRUG), D-serine (DRUG), Cognitive Retraining (CRT) (BEHAVIORAL), Cognitive Retraining Placebo (BEHAVIORAL).
Who is sponsoring clinical trial NCT00237809?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00237809 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.